TP53 MUTATIONS AND DEL17P13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Cerri, M. [1 ]
Deambrogi, C. [1 ]
Capello, D. [1 ]
Cresta, S. [1 ]
Rasi, S. [1 ]
Sozzi, E. [2 ]
De Paoli, L. [1 ]
Gattei, V. [3 ]
Forconi, F. [2 ]
Gaidano, G. [1 ]
Rossi, D. [1 ]
机构：
[1] Amedeo Avogadro Univ, Div Hematol, Novara, Italy
[2] Univ Siena, Div Hematol & Bone Marrow Transplantat, I-53100 Siena, Italy
[3] CRO, Clin & Expt Oncohematol Unit, Aviano, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0410
引用
收藏
页码：163 / 164
页数：2
相关论文
共 50 条
  • [31] Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations
    Wang, Wei
    Routbort, Mark
    Loghavi, Sanam
    Tang, Zhenya
    Medeiros, L. Jeffrey
    Wang, Sa
    LABORATORY INVESTIGATION, 2018, 98 : 563 - 563
  • [32] Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53) Deletion in Chronic Lymphocytic Leukemia
    Chang, Hong
    Jiang, Allan M.
    Qi, Connie X. Y.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 133 (01) : 70 - 74
  • [33] Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes
    Collado, Rosa
    Puiggros, Anna
    Antonio Lopez-Guerrero, Jose
    Jose Calasanz, Ma
    Jose Larrayoz, Ma
    Ivars, David
    Garcia-Casado, Zaida
    Abella, Eugenia
    Teresa Orero, Ma
    Talavera, Elisabet
    Carla Oliveira, Ana
    Ma Hernandez-Rivas, Jesus
    Hernandez-Sanchez, Maria
    Luno, Elisa
    Valiente, Alberto
    Grau, Javier
    Portal, Inmaculada
    Gardella, Santiago
    Camino Salgado, Anna
    Teresa Gimenez, Ma
    Teresa Ardanaz, Ma
    Campeny, Andrea
    Julio Hernandez, Jose
    Alvarez, Sara
    Espinet, Blanca
    Carbonell, Felix
    CANCER LETTERS, 2017, 409 : 42 - 48
  • [34] Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival
    Chin, Melody
    Sive, Jonathan
    Allen, Christopher
    Roddie, Claire
    Chavda, Selina J.
    Smith, Dean
    Popat, Rakesh
    Rismani, Ali
    D'Sa, Shirley
    Rabin, Neil
    Gale, Rosemary E.
    Yong, Kwee L.
    BLOOD, 2016, 128 (22)
  • [35] TP53 Mutation Status in Chronic Lymphocytic Leukemia (CLL)
    Viswanatha, D. S.
    Frederick, L. A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 584 - 584
  • [36] Association between TP53 polymorphisms and chronic lymphocytic leukemia
    Zhang, W-J
    Guo, S-L
    Yin, G.
    Wang, G-S
    Wang, Z-R
    Dong, J.
    Li, Q-R
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (23) : 12073 - 12079
  • [37] Telomere status in chronic lymphocytic leukemia with TP53 disruption
    Guieze, Romain
    Pages, Melanie
    Veronese, Lauren
    Combes, Patricia
    Lemal, Richard
    Gay-Bellile, Mathilde
    Chauvet, Martine
    Callanan, Mary
    Kwiatkowski, Fabrice
    Pereira, Bruno
    Vago, Philippe
    Bay, Jacques-Olivier
    Tournilhac, Olivier
    Tchirkov, Andrei
    ONCOTARGET, 2016, 7 (35) : 56976 - 56985
  • [38] The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia
    Wang, Cheng
    Wang, Xin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2013, 6 (07): : 1223 - 1229
  • [39] Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges
    Edenhofer, Simone A.
    Stilgenbauer, Stephan
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (06) : 381 - +
  • [40] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
    M Chin
    J I Sive
    C Allen
    C Roddie
    S J Chavda
    D Smith
    P Blombery
    K Jones
    G L Ryland
    R Popat
    A Rismani
    S D'Sa
    N Rabin
    R E Gale
    K L Yong
    Blood Cancer Journal, 2017, 7 : e610 - e610
12345